查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1968498

泪囊炎市场－全球产业规模、份额、趋势、机会、预测：按适应症、通路、地区和竞争格局划分，2021-2031年

Dacryocystitis Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球泪囊炎市场预计将从 2025 年的 2.0869 亿美元成长到 2031 年的 2.6621 亿美元，复合年增长率为 4.14%。

该市场涵盖由鼻泪管阻塞引起的泪囊发炎的诊断和治疗性介入，这种疾病会导致疼痛性肿胀和流泪过多。推动市场成长的主要因素包括全球人口老化，老龄化罹患泪道狭窄的风险较高，以及脸部创伤和需要医疗干预的慢性眼部感染疾病不断增加。

市场概览
预测期 2027-2031
市场规模：2025年 2.0869亿美元
市场规模：2031年 2.6621亿美元
复合年增长率：2026-2031年 4.14%
成长最快的细分市场 急性期
最大的市场 北美洲

此外，儿童先天性鼻泪管阻塞的稳定发生率确保了药物治疗和手术矫正的稳定需求，从而建立了不受技术趋势波动影响的稳定市场基础。然而，术后失败的风险以及再血管再阻塞难以处理等因素阻碍了市场扩张。復发率可能会使患者望而却步，并可能影响保险报销。根据美国眼整形与重组外科学会2024年的数据，鼻泪管吻合术的手术成功率在85.3%至91.4%之间，这意味着仍有持续失败的可能，进而影响长期临床疗效。

市场驱动因素

老年人口的快速成长是全球泪囊炎市场的主要驱动因素，老年人极易感染眼部感染疾病。随着人口结构老化加剧，与老龄化的鼻泪管阻塞的发生率显着上升，从而对药物和手术治疗方法产生了持续的需求。由于与老龄化相关的生理变化会损害泪液排放系统，因此老年人群对市场收入尤其重要。根据美国国立卫生研究院 (NIH) 2024 年 4 月发布的一份报告，65 岁及以上人群的视力相关疾病盛行率仍然很高，约为每 10 万人中有 40,966 例，这表明眼科患者数量持续增长。

同时，内视镜技术和雷射治疗的日益普及正在改变市场格局。这些技术为传统体外手术提供了微创替代方案，透过减少脸部疤痕和缩短恢復时间，提高了患者的接受度。根据2024年3月《美国耳鼻喉科杂誌》的报道，初次内视镜下鼻泪管吻合术的一年功能成功率达92.62%。此外，该技术的适用人群正在向更年轻的群体扩展。根据2024年6月《美国儿童与儿童眼科协会杂誌》的报道，儿童急性泪囊炎的发生率为每10万人243例，凸显了各年龄层对专业照护的需求。

市场挑战

术后失败率高以及血管再阻塞处理相关的生理难题是全球泪囊炎治疗市场成长的主要障碍。这种临床上的不确定性削弱了患者对手术治疗的信心，尤其是在老年患者中，他们难以从侵入性手术中恢復，从而阻碍了市场扩张。当治疗的主要疗效因復发风险而降低时，选择性泪道手术的普及速度就会放缓，而再次手术的需求也会给医保报销模式带来复杂的问题，因为支付方需要评估高再治疗率干预措施的长期价值。

近期行业数据进一步凸显了临床疗效方面持续存在的差距，并强调了现有标准疗法的局限性。美国眼科学会 (ARVO) 引用的一项 2024 年临床队列研究发现，约 19.6% 的泪囊炎患者在接受手术治疗后仍有流泪过多的问题。这项统计数据显示症状缓解率极低，并对相关手术器械和疗法的商业性可行性产生了负面影响。只要近五分之一的患者仍面临持续性症状，市场在将这些解决方案推广至更广泛人群方面就将面临挑战。

市场趋势

市场结构性转变的一个显着趋势是泪道手术越来越多地转移到门诊手术中心（ASC）。这主要是由于降低成本和提高营运效率的需求。与传统医院不同，门诊手术中心为泪囊鼻腔吻合术等特定手术提供了高效的环境，有助于降低设施成本并缩短患者等待时间。更优的工作流程指标也支持了这项转变。例如，一篇发表于2024年12月的ASC新闻报导指出，门诊手术中心的平均手术室週转时间约为11.9分钟，这一速度促使支付方和外科医生将常规手术转移到门诊进行。

同时，采用抗生素管理通讯协定正成为应对泪道感染疾病中抗药性病原体日益普遍的关键趋势。随着对标准预防性治疗的抗药性不断增强，临床医生正逐渐抛弃经验性用药，转而采用基于细菌培养的药物治疗，以避免急性泪囊炎治疗失败。鑑于该疾病的细菌学特征日益复杂，这种转变至关重要。根据美国国立卫生研究院2024年2月发布的《成人泪囊炎研究》，抗药性金黄色葡萄球菌（MRSA）和铜绿假单胞菌分别占急性病例分离病原体的28.1%，加速了全球靶向抗菌策略的推广应用。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球泪囊炎市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 适应症（急性、慢性、先天性、泪囊炎、其他）
    • 分销通路（医院药局、药局、网路药局）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美泪囊炎市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲泪囊炎市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区泪囊炎市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲泪囊炎市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲泪囊炎市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球泪囊炎市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Viatris Inc.
  • GlaxoSmithKline PLC
  • FCI Ophthalmics Inc.
  • Merck & Co., Inc.
  • Kaneka Corporation
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Orex Pharma Pvt Ltd

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 23830

The Global Dacryocystitis Market is projected to expand from USD 208.69 Million in 2025 to USD 266.21 Million by 2031, achieving a compound annual growth rate of 4.14%. This market encompasses diagnostic and therapeutic interventions for lacrimal sac inflammation, a condition frequently resulting from nasolacrimal duct obstruction that causes painful swelling and epiphora. Growth is primarily propelled by an aging global population susceptible to involutional stenosis, alongside increasing incidences of facial trauma and chronic ocular infections requiring medical attention.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 208.69 Million
Market Size 2031USD 266.21 Million
CAGR 2026-20314.14%
Fastest Growing SegmentAcute
Largest MarketNorth America

Additionally, the steady prevalence of congenital nasolacrimal duct obstruction in pediatric patients ensures a reliable demand for both pharmaceutical treatments and surgical corrections, creating a stable market foundation irrespective of temporary technological trends. However, market expansion faces hurdles due to the risks associated with post-surgical failure and the difficulties of managing restenosis, as recurrence rates can discourage patients and complicate reimbursement. Data from the American Society of Ophthalmic Plastic and Reconstructive Surgery in 2024 indicated that surgical success rates for dacryocystorhinostomy ranged from 85.3% to 91.4%, underscoring a persistent margin of failure that affects long-term clinical results.

Market Driver

The rapidly growing geriatric population, which is highly susceptible to ocular infections, acts as a major driver for the Global Dacryocystitis Market. As demographics shift toward an older median age, the incidence of involutional nasolacrimal duct obstruction rises substantially, generating consistent demand for pharmacological and surgical solutions. This demographic is particularly vital for market revenue due to age-related physiological changes that impair the lacrimal drainage system. According to the National Institutes of Health in April 2024, the prevalence of vision-related conditions remains severe among those aged 65 and older, affecting approximately 40,966 per 100,000 individuals and ensuring a steady stream of patients for ophthalmologic care.

Simultaneously, the market is being transformed by the increasing utilization of endoscopic techniques and laser therapies, which offer minimally invasive alternatives to conventional external surgeries. These advancements improve patient uptake by reducing facial scarring and recovery times, with the American Journal of Otolaryngology reporting in March 2024 that primary endoscopic dacryocystorhinostomy achieved a 92.62% functional success rate after one year. Furthermore, the market's scope extends to younger populations; the Journal of AAPOS noted in June 2024 that the incidence of acute dacryocystitis in pediatric groups stands at 243 per 100,000, emphasizing the need for specialized care across all age demographics.

Market Challenge

The significant potential for post-surgical failure and the physiological difficulties involved in managing restenosis present a major obstacle to the growth of the Global Dacryocystitis Market. This clinical uncertainty suppresses market expansion by eroding patient confidence in surgical options, particularly among the elderly for whom recovery from invasive procedures is more challenging. When the primary benefit of treatment is undermined by the risk of recurrence, the adoption of elective lacrimal surgeries slows, while the need for revision procedures creates complications for reimbursement models as payers evaluate the long-term value of interventions with high re-treatment rates.

Recent industry data further illuminates this persistent gap in clinical efficacy, highlighting the limitations of existing standard-of-care treatments. A 2024 clinical cohort study cited by the Association for Research in Vision and Ophthalmology found that approximately 19.6% of patients continued to suffer from epiphora even after surgical intervention for dacryocystitis. This statistic indicates a notable failure rate regarding symptom resolution, which negatively affects the commercial viability of surgical devices and therapeutics; as long as nearly one in five patients experiences persistent symptoms, the market encounters difficulties in expanding these solutions to a wider audience.

Market Trends

A significant structural shift in the market is the migration of lacrimal procedures to Ambulatory Surgical Centers (ASCs), driven by the demand for cost containment and operational efficiency. Unlike traditional hospital settings, ASCs offer a high-throughput environment tailored for elective surgeries like dacryocystorhinostomy, which helps decrease facility fees and patient waiting times. This transition is supported by superior workflow metrics; for instance, an article in ASC News from December 2024 regarding ophthalmology trends noted that the average operating room turnover time in ambulatory facilities was approximately 11.9 minutes, illustrating the agility that encourages payers and surgeons to move routine interventions to outpatient settings.

Concurrently, the implementation of antibiotic stewardship protocols is emerging as a crucial trend in response to the rising prevalence of drug-resistant pathogens in lacrimal infections. As resistance to standard prophylactic treatments grows, clinicians are shifting from empirical prescribing to culture-guided pharmacotherapy to avoid treatment failures in acute dacryocystitis. This change is vital given the increasingly complex bacteriological profile of the condition; according to a February 2024 study by the National Institutes of Health on adult dacryocystitis, methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa each constituted 28.1% of isolated pathogens in acute cases, accelerating the global adoption of targeted antimicrobial strategies.

Key Market Players

  • Viatris Inc.
  • GlaxoSmithKline PLC
  • FCI Ophthalmics Inc.
  • Merck & Co., Inc.
  • Kaneka Corporation
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Orex Pharma Pvt Ltd

Report Scope

In this report, the Global Dacryocystitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dacryocystitis Market, By Indication

  • Acute
  • Chronic
  • Congenital
  • Dacryocystitis
  • Other

Dacryocystitis Market, By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores
  • Online Pharmacies

Dacryocystitis Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dacryocystitis Market.

Available Customizations:

Global Dacryocystitis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dacryocystitis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Acute, Chronic, Congenital, Dacryocystitis, Other)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Dacryocystitis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Dacryocystitis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Dacryocystitis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Dacryocystitis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Distribution Channel

7. Europe Dacryocystitis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Dacryocystitis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Dacryocystitis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Dacryocystitis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Dacryocystitis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Dacryocystitis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Dacryocystitis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Dacryocystitis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Dacryocystitis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Dacryocystitis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Dacryocystitis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Dacryocystitis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Dacryocystitis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Dacryocystitis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Dacryocystitis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Dacryocystitis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Distribution Channel

10. South America Dacryocystitis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Dacryocystitis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Dacryocystitis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Dacryocystitis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Dacryocystitis Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Viatris Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. GlaxoSmithKline PLC
  • 15.3. FCI Ophthalmics Inc.
  • 15.4. Merck & Co., Inc.
  • 15.5. Kaneka Corporation
  • 15.6. Aurobindo Pharma Limited
  • 15.7. Bausch Health Companies Inc.
  • 15.8. Orex Pharma Pvt Ltd

16. Strategic Recommendations

17. About Us & Disclaimer